Search results
Results from the WOW.Com Content Network
7 + 3 (Cytarabine + Daunorubicin) is a Chemotherapy Regimen for Acute Myeloid Leukemia (AML) How does 7+3 (cytarabine + daunorubicin) work? Each of the medications in 7+3 is designed to rapidly kill cancer cells in the blood stream and bone marrow. “7” – refers to Cytarabine given daily for 7 days.
For leukemia that has developed particular mutations or has certain other characteristics, a third drug may be added to the 7+3 regimen. These drugs kill AML cells over the first 7 to 14 days, but it takes weeks for the bone marrow to produce enough normal blood cells again.
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less ...
This is called the “7 + 3” regimen, because cytarabine is most often given by continuous intravenous (IV) infusion over 7 days, while the anthracycline drug is given by an IV infusion in a single dose for 3 days during the first week of treatment.
This breakthrough combination and schedule of drugs for AML, widely known as the “7 and 3” regimen, dramatically changed the prognosis of patients, has remained the backbone of standard therapy for close to five decades, and, amazingly, is still going strong.
The expression 7 + 3 stands for a combination of intravenous chemotherapy that includes 7 days of cytarabine (AraC; 100 mg/m 2 per day by continuous infusion) and 3 days of daunorubicin (DNR; 45 mg/m 2 per day, given on days 1, 2, and 3).
This breakthrough combination and schedule of drugs for AML, widely known as the “7 and 3” regimen, dramatically changed the prognosis of patients, has remained the backbone of standard therapy for close to five decades, and, amazingly, is still going strong.
Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia. Blood (2022) 140 (Supplement 1): 1022–1024.
Historically, most centers would treat all eligible and fit AML patients with a standard combination of an anthracycline (usually daunorubicin or idarubicin) IV bolus given for 3 days and continuous infusion cytarabine given for 7 consecutive days, which came to be known as “7 + 3” chemotherapy.
Introduction: Anthracycline- and cytarabine-based induction chemotherapy (IC), known as "7+3", has been the standard of care for fit patients (pts) with AML for over 45 years. While various aspects of IC admissions, such as use of mechanical ventilation and dialysis, admission to intensive care units (ICU), and IC-related mortality have been ...